Linezolid

Introduction Overview

Generic Name

linezolid

Brand Name

Zyvox

Dosage Form

oral tablets, oral suspension, intravenous injection

Drug Class

Oxazolidinone antibiotics

Pharmacokinetics

Absorption:
Linezolid exhibits excellent oral bioavailability, approximately 100%, allowing the oral and intravenous formulations to be used interchangeably. After oral administration, peak plasma concentrations are typically reached within 1 to 2 hours. The absorption is not significantly affected by food, permitting administration with or without meals. The high and consistent absorption profile contributes to predictable and reliable systemic exposure in various patient populations.

Distribution:
Linezolid distributes widely throughout body tissues and fluids, including pulmonary epithelial lining fluid, skin, and soft tissues, which are key sites of infection. It displays moderate plasma protein binding of approximately 31%. The volume of distribution is close to total body water, estimated between 40 to 50 liters, indicating extensive tissue penetration. This widespread distribution supports its efficacy against deep-seated infections including pneumonia and complicated skin infections.

Metabolism:
Linezolid is metabolized primarily by non-enzymatic oxidation, generating two inactive metabolites: aminoethoxyacetic acid and hydroxyethyl glycine. Unlike many antibiotics, linezolid’s metabolism does not involve cytochrome P450 enzymes, reducing the likelihood of metabolic drug interactions. The metabolic process is not saturable and is relatively consistent across different patient demographics, including elderly and renally impaired patients.

Elimination:
The elimination half-life of linezolid averages 4.5 to 5.5 hours, permitting twice-daily dosing. Approximately 30% to 40% of the administered dose is excreted unchanged in the urine, while metabolites are also renally eliminated. In patients with renal impairment, no dosage adjustment is generally required, although accumulation of metabolites may occur. Clearance pathways and elimination remain efficient in hepatic impairment as well, making linezolid suitable for broad patient populations. The drug is not extensively cleared by hemodialysis.

Dosage Forms

Available Dosage Forms:
Zyvox is commercially available as oral tablets, oral suspension (liquid), and intravenous injection formulations. Oral tablets commonly include strengths of 600 mg. The oral suspension contains 100 mg/5 mL. The intravenous form is supplied as a 2 mg/mL solution for infusion.

Dosages for Adults and Adolescents:
The typical adult dose is 600 mg administered orally or intravenously every 12 hours. Duration of therapy depends on the infection type and clinical response, generally ranging from 10 to 28 days. Extended therapy beyond 28 days is possible but requires close monitoring for hematologic and neurologic adverse effects.

Specific Patient Populations:
No dosage adjustments are generally necessary in patients with renal impairment or mild to moderate hepatic impairment. Pediatric dosing differs and is weight-based, but Zyvox is mainly indicated for adults and adolescents over the age of 12. In patients with phenylketonuria (PKU), the oral suspension should be used cautiously or avoided due to phenylalanine content. Pregnant and breastfeeding patients require careful assessment of benefit versus risk. Frequent laboratory monitoring is recommended for long-term therapies and patients with bone marrow suppression or immunosuppression.

Mechanism Of Action

Zyvox (linezolid) exerts its antibacterial effect by inhibiting bacterial protein synthesis at an early stage. Specifically, linezolid binds to the 23S ribosomal RNA of the 50S subunit of bacterial ribosomes, preventing the formation of the functional 70S initiation complex that is essential for the translation process. This unique binding site is distinct from that of other antibiotic classes, conferring activity against strains resistant to other agents.

The inhibition mechanism interrupts the initiation phase of protein synthesis rather than elongation or termination, which limits bacterial growth and leads to a bacteriostatic effect against most susceptible organisms, although bactericidal activity has been observed against certain streptococci. This mode of action is effective against a variety of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

Linezolid also functions as a reversible, non-selective inhibitor of monoamine oxidase (MAO), which has clinical implications regarding serotonin syndrome when combined with serotonergic agents. This MAO inhibition differentiates Zyvox from other antibiotics and necessitates caution with concomitant use of drugs affecting serotonergic pathways.

Clinically, linezolid’s distinct binding and action enable it to overcome resistance mechanisms involving modification of ribosomal targets that render other antibiotics ineffective. Ongoing research supports its efficacy in treating infections caused by multidrug-resistant Gram-positive pathogens, making it a critical option in hospital- and community-acquired infections that are resistant to conventional therapy.

Pharmacological Actions

Bacteriostatic inhibition of bacterial protein synthesis targeting the 50S ribosomal subunit
Effective against multidrug-resistant Gram-positive bacteria including MRSA and VRE
Unique binding to 23S rRNA, preventing formation of the 70S initiation complex
Reversible, non-selective inhibition of monoamine oxidase enzymes
Capability to penetrate lung tissues and epithelial lining fluid effectively
Resistance to cross-resistance with other antibiotic classes due to distinct mechanism
Modulation of bacterial growth without direct bactericidal activity in most cases
Reduced risk of cytochrome P450 metabolic drug interactions
Anti-infective activity against complicated skin and soft tissue infections
Activity against nosocomial and community-acquired pneumonia pathogens
Therapeutic role in treatment of bacteremia resulting from Gram-positive organisms
Inhibition of initiation complex formation limits bacterial proliferation
Limited impact on human mitochondrial protein synthesis minimizes toxicity
Sustained plasma concentrations with twice-daily dosing regimen
Potential neurological effects related to MAO inhibition necessitating monitoring

Therapeutic Or Clinical Uses

Treatment of hospital-acquired and community-acquired pneumonia caused by susceptible Gram-positive bacteria
Therapy for complicated skin and skin structure infections including diabetic foot infections
Management of infections caused by methicillin-resistant Staphylococcus aureus (MRSA)
Treatment of vancomycin-resistant enterococcal infections (VRE)
Bacteremia secondary to Gram-positive infections
Use in infections where oral therapy is preferred or intravenous therapy is required
Treatment of multidrug-resistant bacterial infections unresponsive to other antibiotics
Off-label use in certain deep-seated infections due to excellent tissue penetration
Alternative therapy for patients allergic to beta-lactams or glycopeptides
Use in patients with renal or mild hepatic impairment without dose adjustment
Management of complicated wounds and post-surgical infections
Treatment of infections caused by penicillin-resistant pneumococci
Part of combination therapy regimens for severe resistant bacterial infections
Considered for infections where oral step-down therapy is advantageous
Used in immunocompromised patients with resistant Gram-positive bacterial infections

Side Or Adverse Effects

Nausea, vomiting, and diarrhea as common gastrointestinal adverse reactions
Skin rash and other dermatological reactions including erythema
Anemia and other hematologic effects such as thrombocytopenia and pancytopenia, particularly with prolonged use
Headache and dizziness reported during treatment courses
Peripheral and optic neuropathy with extended therapy durations
Serotonin syndrome risk when combined with serotonergic drugs, characterized by agitation, hallucinations, fever, and muscle rigidity
Lactic acidosis presenting with muscle pain, dyspnea, and lethargy, requiring urgent attention
Visual disturbances including changes in color vision and blurred vision
Seizures reported rarely in predisposed individuals
Oral and vaginal candidiasis due to alteration of normal flora
Thrombocytopenia leading to increased bleeding risk
Peripheral neuropathy symptoms such as numbness and paresthesia
Reversible bone marrow suppression with prolonged administration
Hypoglycemia episodes, especially in diabetic patients or those on antidiabetic agents
Allergic reactions including anaphylaxis and Stevens-Johnson syndrome

Precautions

Do not use in patients with known hypersensitivity to linezolid or any component of Zyvox
Avoid concomitant use with monoamine oxidase inhibitors or serotonergic agents to prevent serotonin syndrome
Caution in patients with a history of hypertension or uncontrolled high blood pressure due to tyramine interactions
Monitor blood counts regularly during prolonged therapy owing to risk of bone marrow suppression
Perform frequent vision assessments during extended courses to detect early optic neuropathy
Use cautiously in patients with liver or kidney impairment although dose adjustment generally unnecessary
Avoid tyramine-rich foods to prevent hypertensive crises during treatment
Patients with phenylketonuria should avoid oral suspension due to phenylalanine content
Assess risk-benefit carefully in pregnant or breastfeeding women before initiating therapy
Monitor for signs of lactic acidosis, especially in patients with predisposing conditions
Careful evaluation in patients with seizure disorders as linezolid may lower seizure threshold
Use in immunocompromised patients requires close monitoring for superinfections
Promptly report any neuropsychiatric symptoms during therapy
Avoid abrupt discontinuation of serotonergic medications without medical advice while on Zyvox
Educate patients about recognizing symptoms of serotonin syndrome and hypertensive crises

Warnings

Risk of serotonin syndrome with concomitant use of serotonergic and MAO-inhibiting drugs
Potential for lactic acidosis necessitating immediate discontinuation if symptoms appear
Development of optic and peripheral neuropathy, especially when used longer than 28 days
Hematologic toxicity, including thrombocytopenia and anemia, more common with prolonged use
Hypertensive crisis from dietary tyramine ingestion during therapy with linezolid
Severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis possible
Not to be used in patients treated with other MAO inhibitors within the previous 14 days
Avoid use if untreated or uncontrolled hypertension, pheochromocytoma, or hyperthyroidism are present
Close monitoring required in patients receiving linezolid with antidepressant medications
May cause hypoglycemia, particularly in diabetic patients under antidiabetic therapy
Serious allergic reactions including angioedema and anaphylaxis reported rarely
Risk of Clostridioides difficile-associated diarrhea with broad-spectrum antibiotic use
Avoid unnecessary long duration of therapy to reduce adverse effect incidence
Use caution when administering to neonates and children due to limited data
Regular laboratory and clinical monitoring mandated to detect early adverse reactions

Contraindication

Known hypersensitivity or allergy to linezolid or any excipients in Zyvox formulations
Concurrent or recent (within 14 days) use of monoamine oxidase inhibitors (MAOIs) such as isocarboxazid, phenelzine, tranylcypromine, or methylene blue
Patients with uncontrolled high blood pressure or cardiovascular instability
Untreated or uncontrolled carcinoid tumor or pheochromocytoma
Severe hepatic impairment where drug metabolism may be affected (use with caution)
Concomitant use with serotonergic psychiatric medications without appropriate monitoring
Known hypersensitivity to any component of the oral suspension, including phenylalanine in PKU patients
Use in patients with previous serotonergic toxicity or serotonin syndrome
Contraindicated in patients with a history of hemolytic reactions or severe hematologic disorders without careful evaluation
Concurrent treatment with drugs that may precipitate hypertensive crisis without strict supervision

Drug Interactions

Significant interaction with monoamine oxidase inhibitors leading to serotonin syndrome
Concomitant use with selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), or tricyclic antidepressants increases risk of serotonin syndrome
Interaction with sympathomimetic drugs (e.g., pseudoephedrine, phenylephrine) causing hypertensive episodes
Potential potentiation of hypoglycemic effects when used with antidiabetic agents
Increased risk of bleeding with concomitant use of anticoagulants (warfarin) requiring monitoring of coagulation parameters
Interaction with opioid analgesics increasing serotonergic activity and adverse CNS effects
Caution with stimulant medications used in Parkinson’s disease or attention deficit disorders
Potential interaction with herbal supplements such as St. John's Wort affecting serotonergic pathways
No significant cytochrome P450 mediated drug interactions limiting metabolic interactions
Elevated blood pressure risk when combined with tyramine-rich foods during linezolid therapy
Possible additive myelosuppressive effects with other bone marrow toxic drugs
Interaction with serotonergic antiemetics and migraine medications (e.g., triptans) elevates serotonin syndrome risk
Patients should avoid starting or stopping other medications without physician guidance during treatment
Linezolid may increase the effects of adrenergic agents leading to cardiovascular side effects
Concurrent use with methylene blue is contraindicated due to enhanced MAO inhibition

Preparations Of The Drug

Oral tablets: 600 mg strength for twice-daily dosing
Oral suspension: 100 mg/5 mL concentration; note phenylalanine content relevant to PKU patients
Intravenous injection: 2 mg/mL solution for infusion, supplied in single-use vials
Solutions prepared for injection must be used immediately or stored as per manufacturer’s guidelines; discard if particulates are present
Dosing syringe and measuring devices provided with oral suspension for accurate dosing
Packaging designed to protect from moisture, heat, and light; storage at room temperature recommended
Oral suspension to be gently mixed by inversion but not shaken
Discard oral suspension 21 days after opening to maintain drug stability
Intravenous infusion generally administered over 30 to 120 minutes by healthcare professionals
Detailed instructions and patient information leaflets provided to ensure proper administration
Commercial preparations meet pharmacopeial standards for purity and potency
Available both as brand-name Zyvox and generic linezolid formulations
Repackaging and compounding should adhere strictly to stability and sterility protocols
All preparations require prescription and medical supervision due to potential side effects and interactions
Proper disposal instructions provided to prevent environmental contamination and accidental exposure